Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (132)	1/11/1999 11:07:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 179

Hi Richard, I recently spoke with PCOP on this agreement. It is a smaller form of collaboration. PCOP only expects it to bring in 1 to 2 million annually. The up side of my conversation included added perspective on the companies status of turning profitable over the next year. An upcoming significant collaboration with a "new" Big Pharma partnership. The fact that the dilution from prior venture capitalists is all but out. The potential dilution from the remaining 5 million shares ( CORNING ) is muted and may not even occur. Finally the patent issue with Affemex is looking more like a negotiable issue based on recent patent rights PCOP has established relative to AFFX position ( One hand washes the other ). Hence I believe this reduced dilution issue along with the positive events forthcoming should result in a good year for PCOP shareholders provided Corning et al remains long. The stock has a little way to go before a breakout can be predicted. But having followed PCOP for close to 2 years I'd say things are looking their best since last Jan. clearstation.com BEST WISHES LONE WOLF

To: scaram(o)uche who wrote (132)	1/19/1999 1:28:00 PM
From: kinkblot	Respond to of 179

Pharmacopeia and Pharmacia & Upjohn Form Research Collaboration: PRINCETON, NJ (January 19, 1999) - Pharmacopeia, Inc. (Nasdaq: PCOP) today announced the signing of a new multi-year, multi-target research collaboration with Pharmacia & Upjohn Inc. Under the terms of the agreement, Pharmacopeia will screen its multi-million compound sample collection of diverse, small molecules against numerous targets chosen by Pharmacia & Upjohn each year. In addition to annual guaranteed payments, Pharmacia & Upjohn will make further payments based on the success of the screening programs. Optimization of active compounds identified by Pharmacopeia may be performed either by Pharmacia & Upjohn or by Pharmacopeia, for additional consideration. Financial terms of the agreement were not disclosed. ...[continued] pharmacopeia.com .................... At least the stock responded positively this time. Maybe their stockpile of molecules is finally approaching 'critical mass'.